Racemisation and Chiral Purity in Synthetic Peptides
Every amino acid in a synthetic peptide is supposed to be the L form. Some fraction will not be, and the impurity that results is invisible to the two tests most certificates rely on. It has the same mass as the target and, frequently, the same retention time.
Where the D residue comes from
During solid-phase synthesis each residue is activated before coupling, and activation makes the alpha proton more acidic. Under basic conditions that proton can be removed and replaced from either face, inverting the stereocentre. The result is a D residue sitting in an otherwise L sequence.
The rate is not uniform. Cysteine and histidine racemise far more readily than most residues, because their side chains stabilise the intermediate. Serine and aspartic acid are also above average. A sequence containing several of these is a harder synthesis than its length alone suggests, and the same peptide made by two houses can differ measurably in chiral purity.
Why the usual tests miss it
A peptide with one inverted residue is a diastereomer of the target. It contains exactly the same atoms in exactly the same order, so:
- Mass spectrometry cannot see it. The mass is identical to the parent, not one dalton away as with deamidation and not sixteen as with oxidation. There is no satellite peak to find.
- Diode-array peak purity cannot see it. The UV spectrum is the same, so a spectral comparison across the peak returns no difference.
- Reversed-phase HPLC often cannot resolve it. Diastereomers do differ slightly in hydrophobicity, so they sometimes separate, but the difference is small and frequently smaller than the peak width. When it does not separate, it is counted as target. Co-elution covers that mechanism.
The consequence is that a 99% purity figure from HPLC and a clean mass spectrum are both consistent with a material carrying several percent of diastereomeric impurity.
How chiral purity is actually measured
Two approaches, both separate from routine characterisation.
Chiral amino acid analysis. The peptide is hydrolysed to free amino acids, those are derivatised, and the D and L forms of each residue are separated and quantified — by chiral gas chromatography or by a chiral HPLC column. This reports the D content residue by residue, which is the informative answer. Its limitation is that hydrolysis itself causes some racemisation, so a small background is always present and a good laboratory reports the blank.
Chiral or orthogonal separation of the intact peptide. Slower and less sensitive per residue, but it leaves the molecule intact and avoids the hydrolysis artefact.
Neither is part of a standard identity and purity package, and neither appears on the certificates most suppliers publish.
What this means when reading a certificate
Take it as a limit on what the document covers rather than a reason to distrust it. A certificate reporting HPLC purity and a measured mass has established what those two methods establish. Chiral purity is simply outside that scope, in the same way sterility and endotoxin are. What a third-party peptide test actually measures works through the whole document, and HPLC and mass spectrometry in purity verification covers what the two together can and cannot resolve.
Where stereochemistry matters to the work, it has to be asked for by name. It will not arrive by default.
All material is supplied for laboratory research use only. It is not a drug, not a supplement, and not for use in humans or animals.
